Showing results (1-10 of 132) with videos related to
Sort By:
Pageof 14
Experimental and Clinical Cardiology|July 31, 2009
The role of ryanodine receptors and consequences of their alterations during cardiac insufficiencyGuy Vassort, Alain LacampagnePflugers Archiv : European Journal of Physiology|February 22, 2011
Regional variation in myofilament length-dependent activationOlivier Cazorla, Alain LacampagneCurrent Opinion in Pharmacology|February 5, 2008
New insights into mechanisms of statin-associated myotoxicityPascal Sirvent, Jacques Mercier, Alain LacampagneMedecine Sciences : M/S|April 15, 2008
[Ryanodine receptor and heart disease]Alain Lacampagne, Jérémy Fauconnier, Sylvain RichardCell Death & Disease|November 2, 2021
"Ryanopathies" and RyR2 dysfunctions: can we further decipher them using in vitro human disease models?Yvonne Sleiman, Alain Lacampagne, Albano C MeliPharmacology & Therapeutics|February 7, 2013
Type 2 ryanodine receptor: a novel therapeutic target in myocardial ischemia/reperfusionJérémy Fauconnier, Stéphanie Roberge, Nathalie Saint, et al.British Journal of Pharmacology|May 15, 2003
SR33805, a Ca2+ antagonist with length-dependent Ca2+ -sensitizing properties in cardiac myocytesOlivier Cazorla, Alain Lacampagne, Jeremy Fauconnier, et al.Biochemical and Biophysical Research Communications|March 9, 2005
Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal musclePascal Sirvent, Jacques Mercier, Guy Vassort, et al.FEBS Letters|May 2, 2009
Fem1a is a mitochondrial protein up-regulated upon ischemia-reperfusion injuryLinda Cambier, Alain Lacampagne, Charles Auffray, et al.Expert Review of Cardiovascular Therapy|December 25, 2016
Anti-inflammatory drugs as promising cardiovascular treatmentsFabien Huet, Mariama Akodad, Jérémy Fauconnier, et al.Pageof 14